Bio Techne : Corporate Presentation – June 2021

WHERE SCIENCE INTERSECTS INNOVATIONT M

C o r p o r a t e P r e s e n t a t i o n J u n e 2 0 2 1

© 2021 Bio-Techne®. All rights reserved.

SAFE HARBOR

C A U T I O N A R Y S TA T E M E N T S

This presentation contains "forward-looking statements" within the meaning of the federal securities laws. Except for historical information contained herein, the statements in this presentation are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements made herein relate to, among other things, future sales, earnings, return on equity, cost savings, process improvements, free cash flow, share repurchases, capital expenditures, acquisitions, benefits of investments and partnerships, business strategies, the potential impact of COVID-19 on our operations or financial results and other matters. Such statements can be identified by words such

as: "expected," "expects," "expect," "forecast," "would," "estimate," "will," or similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results could differ materially from those stated or implied in the forward-looking statements. For a list of factors, risks and uncertainties which could make our actual results differ from expected results, please see our latest Annual Report on Form 10-K. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, as a result of new information, future developments or otherwise.

This presentation also contains non-GAAP financial information. Management uses this information in its internal analysis of results and believes this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results and providing meaningful period-to-period comparisons. For definitions of applicable non-GAAP financial measures and reconciliations of non-GAAP financial information to GAAP financial information, see the Reconciliations of GAAP to Non-GAAP Financial Measures included in the Company's financial reports on Forms 10-Q and 10-K and related press releases.

2

CONFIDENTIAL

© 2021 Bio-Techne®. All rights reserved.

B U S I N E S S O V E RV I E W

P R E S I D E N T A N D C E O

Chuck Kummeth

H E A D Q U A R T E R S

Minneapolis, MN

N U M B E R O F E M P L O Y E E S

~2,600

W O R L D W I D E P R E S E N C E

35 Locations

F Y 2 0 2 0 R E V E N U E S

$739M

N A S D A Q

TECH

M A R K E T C A P

~$16B

10%6%2%

I N S T R U M E N T S S E R V I C E S R O Y A L T I E S

82%

C O N S U M A B L E S

PROTEINSANTIBODIES

AUTOMATED PROTEIN

ANALYSISIMMUNOASSAYS

TISSUE PATHOLOGY

LIQUID BIOPSY

DIAGNOSTIC	DIAGNOSTIC
KITS	REAGENTS

© 2021 Bio-Techne®. All rights reserved.

3

© 2021 Bio-Techne®. All rights reserved.

FY20 REVENUE BY CUSTOMER

TYPE & GEOGRAPHY

22%		$739M
		18%
O E M	17%		A S I A
	D I S T R I B U T O R S
23%				57%
	25	%	A M E R I C A S
A C A D E M I A

E M E A

38%

P H A R M A / B I O T E C H

© 2021 Bio-Techne®. All rights reserved.

4

FOUR KEY STRATEGIES FOR

SUSTAINED GROWTH

G E O G R A P H I C	C O R E P R O D U C T	G A P F I L L I N G M & A	C U LT U R E
E X PA N S I O N	I N N O V AT I O N	A N D M A R K E T	C R E AT I O N
		E X PA N S I O N	A N D TA L E N T

© 2021 Bio-Techne®. All rights reserved.

5